JP2015078230A5 - - Google Patents

Download PDF

Info

Publication number
JP2015078230A5
JP2015078230A5 JP2015006124A JP2015006124A JP2015078230A5 JP 2015078230 A5 JP2015078230 A5 JP 2015078230A5 JP 2015006124 A JP2015006124 A JP 2015006124A JP 2015006124 A JP2015006124 A JP 2015006124A JP 2015078230 A5 JP2015078230 A5 JP 2015078230A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
following formula
acceptable salt
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015006124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015078230A (ja
JP5963894B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015078230A publication Critical patent/JP2015078230A/ja
Publication of JP2015078230A5 publication Critical patent/JP2015078230A5/ja
Application granted granted Critical
Publication of JP5963894B2 publication Critical patent/JP5963894B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2015006124A 1999-12-03 2015-01-15 ホスホネート化合物 Expired - Lifetime JP5963894B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16881399P 1999-12-03 1999-12-03
US60/168,813 1999-12-03
US20571900P 2000-05-19 2000-05-19
US60/205,719 2000-05-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011153911A Division JP2011246475A (ja) 1999-12-03 2011-07-12 ホスホネート化合物

Publications (3)

Publication Number Publication Date
JP2015078230A JP2015078230A (ja) 2015-04-23
JP2015078230A5 true JP2015078230A5 (enExample) 2015-12-24
JP5963894B2 JP5963894B2 (ja) 2016-08-03

Family

ID=26864475

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2001541459A Expired - Lifetime JP4993649B2 (ja) 1999-12-03 2000-12-04 ホスホネート化合物
JP2011153911A Withdrawn JP2011246475A (ja) 1999-12-03 2011-07-12 ホスホネート化合物
JP2014002881A Expired - Lifetime JP5963787B2 (ja) 1999-12-03 2014-01-10 ホスホネート化合物
JP2015006124A Expired - Lifetime JP5963894B2 (ja) 1999-12-03 2015-01-15 ホスホネート化合物

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2001541459A Expired - Lifetime JP4993649B2 (ja) 1999-12-03 2000-12-04 ホスホネート化合物
JP2011153911A Withdrawn JP2011246475A (ja) 1999-12-03 2011-07-12 ホスホネート化合物
JP2014002881A Expired - Lifetime JP5963787B2 (ja) 1999-12-03 2014-01-10 ホスホネート化合物

Country Status (18)

Country Link
US (14) US6716825B2 (enExample)
EP (1) EP1233770B1 (enExample)
JP (4) JP4993649B2 (enExample)
KR (1) KR20020073342A (enExample)
CN (1) CN1414854B (enExample)
AT (1) ATE385797T1 (enExample)
AU (3) AU785355B2 (enExample)
BR (1) BR0016058A (enExample)
CA (2) CA2747954C (enExample)
CY (1) CY1107927T1 (enExample)
DE (1) DE60038038T2 (enExample)
DK (2) DK1914237T3 (enExample)
ES (2) ES2300281T3 (enExample)
HK (1) HK1050627B (enExample)
MX (1) MXPA02005490A (enExample)
PT (2) PT1914237E (enExample)
RU (1) RU2258707C2 (enExample)
WO (1) WO2001039724A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
BR0016058A (pt) * 1999-12-03 2003-07-15 Univ California San Diego Compostos de fosfonato
US7163932B2 (en) * 2001-06-20 2007-01-16 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
WO2003008425A1 (fr) * 2001-07-16 2003-01-30 Universite Paris 13 Nouveaux derives de bisphosphonates, leurs preparations et utilisations
FR2837490B1 (fr) * 2002-03-21 2009-04-17 Univ Paris 13 Nouveaux derives de bisphosphonates, leurs preparations et utilisations
EP1490024B1 (en) * 2002-03-06 2012-01-18 EffRx Pharmaceuticals SA Effervescent compositions comprising alendronate
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
WO2003090691A2 (en) * 2002-04-26 2003-11-06 Gilead Sciences, Inc. Method and compositions for identifying anti-hiv therapeutic compounds
RU2309747C2 (ru) * 2002-09-18 2007-11-10 Михаил Владимирович Кутушов Применение 2-хлорэтилфосфоновой кислоты и ее солей в качестве противоопухолевого средства
AU2003901813A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
JP2006524710A (ja) 2003-04-25 2006-11-02 ギリアード サイエンシーズ， インコーポレイテッド キナーゼインヒビターホスホネート抱合体
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7273717B2 (en) 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
JP4692283B2 (ja) * 2003-12-12 2011-06-01 アステラス製薬株式会社 悪性黒色腫治療剤
JP2007515495A (ja) 2003-12-22 2007-06-14 ギリアード サイエンシーズ， インコーポレイテッド ４’−置換カルボビル誘導体およびアバカビル誘導体ならびにｈｉｖおよびｈｃｖ抗ウイルス活性を有する関連化合物
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
WO2006076015A2 (en) * 2004-04-30 2006-07-20 The Regents Of The University Of California 1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
US7504389B2 (en) * 2004-11-15 2009-03-17 Ceptyr, Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
EP1831235B1 (en) 2004-12-16 2013-02-20 The Regents of The University of California Lung-targeted drugs
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20060219637A1 (en) * 2005-03-29 2006-10-05 Killeen Kevin P Devices, systems and methods for liquid chromatography
WO2006130217A2 (en) * 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
JP2008535862A (ja) * 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
EP1865967A4 (en) * 2005-04-08 2011-02-09 Chimerix Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
WO2006114064A2 (en) * 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry Ofthe Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
US7914810B2 (en) * 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
US8114843B2 (en) * 2005-11-18 2012-02-14 The Regents Of The University Of California Photoreactive regulator of protein function and methods of use thereof
WO2007130783A2 (en) 2006-05-03 2007-11-15 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
ES2609095T3 (es) * 2007-04-27 2017-04-18 Chimerix, Inc. Métodos de reducción de la nefrotoxicidad en sujetos a quienes se administra nucleósido
JP2011508740A (ja) * 2007-12-27 2011-03-17 エピファニー バイオサイエンシズ， インク． 抗ウイルス化合物
AU2009206673B2 (en) * 2008-01-25 2015-04-23 Chimerix, Inc. Methods of treating viral infections
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ阻害剤化合物の塩
US8628812B2 (en) * 2008-12-30 2014-01-14 Pepsico, Inc. Preservative system for acidic beverages based on sequestrants
EP2270021A1 (en) * 2009-06-18 2011-01-05 Centre National de la Recherche Scientifique Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
WO2011005510A2 (en) * 2009-06-22 2011-01-13 Cerapedics, Inc. Peptide conjugates and uses thereof
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
WO2011017253A1 (en) 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
CN102639545B (zh) * 2009-10-02 2016-08-03 施里特马克控股公司 制备氨基羟基二膦酸的方法
EP3216789A1 (en) 2010-02-12 2017-09-13 Chimerix, Inc. Methods of treating viral infection
WO2011130557A2 (en) 2010-04-14 2011-10-20 The Regents Of The University Of California Phosphonates with reduced toxicity for treatment of viral infections
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
AU2015201895B2 (en) * 2010-08-31 2016-11-17 Emergent Biodefence Operations Lansing Llc Phosphonate ester derivatives and methods of synthesis thereof
AU2011295937B2 (en) * 2010-08-31 2015-04-16 Emergent Biodefence Operations Lansing Llc Phosphonate ester derivatives and methods of synthesis thereof
US8884027B2 (en) 2010-10-22 2014-11-11 University Of Rochester Melampomagnolide B derivatives as antileukemic and cytotoxic agents
US9216225B2 (en) * 2011-08-31 2015-12-22 Mallinckrodt Llc Remote assembly of targeted nanoparticles using H-phosphate ENE/-YNE hydrophosphonylation reactions
WO2013095684A1 (en) 2011-12-22 2013-06-27 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US20150209273A1 (en) * 2012-08-28 2015-07-30 Glaxosmithkline Llc Pharmaceutical Compositions
CN107056838A (zh) * 2013-03-15 2017-08-18 加利福尼亚大学董事会 无环核苷膦酸二酯
CN105899215A (zh) 2013-11-15 2016-08-24 奇默里克斯公司 十六烷氧基丙基膦酸酯的形态
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
BR112016020233B1 (pt) 2014-03-14 2022-07-19 Alltech Inc. Composições de compostos seleno orgânicos e seus usos
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
SG11201701957XA (en) 2014-09-15 2017-04-27 Univ California Nucleotide analogs
US10160778B2 (en) 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
GEAP202215528A (en) 2015-03-06 2022-11-10 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
CN108135863B (zh) * 2015-04-27 2021-07-27 特拉维夫医疗中心医学研究基础设施和保健服务基金会 用于治疗炎性和过度增殖性病况的egr1靶向分子
WO2017048252A1 (en) 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
ES3037596T3 (en) 2016-06-28 2025-10-03 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
RU2628456C1 (ru) * 2016-06-29 2017-08-17 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Новые пиримидиновые ингибиторы репликации аденовируса человека
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
EP3661937B1 (en) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
RU2670204C1 (ru) * 2017-12-01 2018-10-19 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Производные 2-тиоурацила, обладающие противоаденовирусной активностью
JP7076158B2 (ja) * 2017-12-21 2022-05-27 深▲チェン▼市塔吉瑞生物医薬有限公司 新規抗ウイルス性ヌクレオシド系逆転写酵素阻害剤
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
EP4017499A4 (en) 2019-08-22 2024-01-10 Emory University Nucleoside prodrugs and uses related thereto
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4200301B1 (en) 2020-08-24 2025-02-26 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
CN117285566A (zh) * 2022-06-24 2023-12-26 润佳（苏州）医药科技有限公司 一种膦酸酯类化合物及其医药用途
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1944530A (en) 1929-04-08 1934-01-23 Ig Farbenindustrie Ag Phosphoric acid esters
DE2009341C3 (de) 1970-02-27 1979-06-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
FR2586685B1 (fr) * 1985-09-03 1987-12-11 Protex Manuf Prod Chimiq Procede de preparation de nouveaux agents dispersants cationiques
SU1594953A1 (ru) * 1988-12-30 1991-05-15 Институт Молекулярной Биологии Им.В.А.Энгельгардта Аммонийна соль 9-(4-гидрофосфорил-2-оксабутил)гуанина, обладающа избирательной активностью против вируса простого герпеса
FI83421C (fi) * 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
DE69129650T2 (de) 1990-09-14 1999-03-25 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Wirkstoffvorläufer von Phosphonaten
EP0477454A1 (en) * 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
JPH05339280A (ja) * 1991-04-26 1993-12-21 Japan Tobacco Inc （ｎ−二環置換）アミノメチレンビスフォスフォン酸誘導体
JP3341303B2 (ja) * 1991-07-11 2002-11-05 東レ株式会社 メチレンジホスホン酸誘導体、その製造方法およびその医薬用途
US5879700A (en) * 1991-10-15 1999-03-09 Hostetler; Karl Y. Nucleoside analogue phosphates for topical use
EP0603401B1 (en) 1992-07-10 2001-04-11 Toray Industries, Inc. Methanediphosphonate derivative, production thereof, and pharmaceutical use thereof
CA2126601A1 (en) 1993-06-29 1994-12-30 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
JP3580377B2 (ja) * 1993-06-29 2004-10-20 三菱化学株式会社 ホスホナートヌクレオチドエステル誘導体
US5627185A (en) 1994-11-23 1997-05-06 Gosselin; Gilles Acyclovir derivatives as antiviral agents
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
EP0897709B1 (en) * 1996-12-19 2007-02-21 Kao Corporation Coating composition for teeth
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
IL134619A0 (en) * 1997-08-18 2001-04-30 Univ Kingston Phosphono-carboxylate compounds for treating amyloidosis
FR2781228B1 (fr) * 1998-07-16 2000-09-29 Pf Medicament Phosphonates insatures derives d'indole
BR0016058A (pt) * 1999-12-03 2003-07-15 Univ California San Diego Compostos de fosfonato

Similar Documents

Publication Publication Date Title
JP2015078230A5 (enExample)
JP2014221779A5 (enExample)
JP2014507446A5 (enExample)
JP2012255026A5 (enExample)
JP2017105793A5 (enExample)
JP2013014622A5 (enExample)
JP2017537066A5 (enExample)
JP2016518337A5 (enExample)
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
JP2017509667A5 (enExample)
JP2013518107A5 (enExample)
MD20140073A2 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
MX394588B (es) Composición farmacéutica.
JP2017517565A5 (enExample)
JP2014218522A5 (enExample)
JP2011527299A5 (enExample)
PH12015501945B1 (en) Formulations of organic compounds
EA201890532A1 (ru) Новые аннелированные бензамиды
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
RU2017141536A (ru) Замещенные производные индол-5-ола и их терапевтические применения
JP2016532632A5 (enExample)
JP2015516419A5 (enExample)
EP2871187A4 (en) A NEW CONNECTION OR PHARMACEUTICALALLY SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS AN ACTIVE SUBSTANCE
EA201692298A1 (ru) Производные карбоксамидов